House Oversight Committee Chairman James Comer has opened an investigation into a Drug Enforcement Administration practice that allegedly allowed millions of fentanyl pills to pour into New Mexico communities while agents tried to build bigger cases against drug traffickers.
The probe, announced in a letter to Attorney General Pam Bondi and DEA Acting Administrator Robert Murphy, targets a strategy known within the agency as "controlled delivery" or "pass-through," in which agents knowingly permitted large drug shipments to reach their destinations rather than seizing them immediately. The goal, according to the DEA's stated rationale, was to track supply chains and eventually dismantle higher-level trafficking networks. The result, whistleblowers and state officials say, was a flood of deadly narcotics reaching American buyers.
Comer's letter, first reported by the Associated Press, requests documents and communications related to the DEA's use of pass-through operations, particularly those run out of the agency's Albuquerque office. The committee set a deadline of June 19 for the Justice Department and DEA to produce the materials.
The investigation follows a series of whistleblower disclosures and an internal Justice Department inspector general review that examined whether the DEA's Albuquerque division let controlled substances, primarily fentanyl pills, move through trafficking pipelines without adequate safeguards. Whistleblowers told the AP that agents in New Mexico allowed millions of fentanyl pills to reach the streets in pursuit of long-term prosecutions that, in some cases, never materialized.
Comer framed the inquiry in blunt terms. In his letter, the chairman wrote that the committee needed to understand "the full scope of the DEA's use of pass-through drug operations, particularly those that may have resulted in the uncontrolled distribution of fentanyl and other deadly narcotics."
In a typical pass-through operation, DEA agents identify a drug shipment but choose not to intercept it. Instead, they monitor the shipment as it moves through the supply chain, hoping to identify distributors, stash houses, and cartel leadership further up the ladder. The tactic is not new. Federal law enforcement agencies have used variations of it for decades in narcotics and organized crime investigations.
But fentanyl changed the calculus. Unlike cocaine or marijuana, fentanyl is lethal in milligram quantities. A single pill can kill. Critics of the pass-through approach argue that allowing fentanyl shipments to reach end users, even temporarily, creates an unacceptable risk of overdose deaths that no eventual prosecution can undo.
The inspector general's review found that the Albuquerque division's operations lacked consistent documentation and oversight. In some instances, agents could not account for whether all the drugs in a tracked shipment were ultimately recovered. That gap is central to the congressional investigation: if pills slipped out of the DEA's surveillance net, they almost certainly ended up in the hands of users.
Before Comer's committee stepped in, New Mexico's state government had already sounded alarms. Governor Michelle Lujan Grisham demanded a criminal investigation into the DEA's conduct, calling the pass-through operations a betrayal of public trust. Lujan Grisham said the practice put New Mexico residents in danger and questioned whether federal agents bore responsibility for overdose deaths that occurred while tracked shipments were in transit.
New Mexico has been hit particularly hard by the fentanyl crisis. The state consistently ranks among the highest in per-capita overdose death rates. For state officials, the idea that a federal agency deliberately let pills circulate, even as a law enforcement strategy, struck a raw nerve.
The DEA has defended the general concept of pass-through operations as a legitimate investigative tool. Agency officials have said that such operations are subject to internal approval processes and are designed to produce high-value arrests and prosecutions. But the whistleblower accounts suggest those approval processes broke down in practice, at least in New Mexico.
The House Oversight investigation is not limited to the Albuquerque office. Comer's letter asks whether pass-through operations were conducted by other DEA field divisions and whether similar problems with oversight and drug recovery occurred elsewhere. The committee also wants to know what role Justice Department leadership played in approving or supervising the operations.
That question carries political weight. The pass-through operations under scrutiny took place during the Biden administration, when the Justice Department faced persistent criticism from Republicans over its handling of border security and drug enforcement. Comer's investigation gives the committee a concrete case study to examine whether federal law enforcement prioritized case-building metrics over public safety.
The broader pattern of government accountability failures in drug enforcement extends beyond U.S. borders. In Mexico, elected officials have faced drug trafficking charges of their own, raising questions about how deeply cartel influence has penetrated government institutions on both sides of the border.
The June 19 deadline gives the Justice Department and DEA roughly three weeks to produce records. Comer's request covers internal communications, operational plans, approval memoranda, and any after-action reviews related to pass-through operations. The committee also asked for records showing how many pills or drug quantities were tracked, how many were recovered, and how many remain unaccounted for.
Those numbers matter. If the DEA can show that the vast majority of tracked shipments were ultimately seized and that the operations led to significant prosecutions, the agency's defense of the tactic gains credibility. If the records reveal large quantities of unrecovered fentanyl and few major convictions, the case for institutional failure becomes much harder to dismiss.
Federal watchdog agencies have separately flagged concerns about how law enforcement coordinates drug interdiction efforts. A recent government accountability report found that cartels are shifting operations to exploit gaps in federal planning, a finding that underscores the stakes of getting enforcement strategy right.
Whistleblowers who spoke to the AP described a culture within the Albuquerque office where agents felt pressure to pursue large-scale cases, even when the pass-through method carried obvious risks. One whistleblower said agents were told that seizing drugs too early would "burn" investigations and prevent the office from landing headline prosecutions.
For the DEA, the investigation poses both legal and reputational risks. If the committee finds that agents knowingly allowed lethal drugs to reach consumers without adequate controls, the agency could face calls for disciplinary action, policy overhauls, or even referrals for criminal investigation of individual agents or supervisors.
For Congress, the probe fits into a larger Republican effort to hold federal law enforcement accountable for decisions made during the previous administration. Comer has positioned the Oversight Committee as a check on agencies that, in his view, prioritized institutional interests over the safety of American communities.
The corruption and accountability themes extend across the hemisphere. Mexican authorities have also grappled with officials accused of enabling cartel operations, including a former governor arrested over an alleged criminal cover-up tied to the disappearance of 43 students in 2014.
Attorney General Bondi and Acting Administrator Murphy have not publicly commented on Comer's letter. The Justice Department has not indicated whether it will comply fully with the document request or assert any privileges.
If the Justice Department cooperates, the committee could hold public hearings featuring whistleblowers, former DEA officials, and state leaders from New Mexico. If the department resists, Comer has the subpoena power to compel production, setting up a potential confrontation between the executive and legislative branches over law enforcement transparency.
The investigation also raises a question that no document production can fully answer: how many people died from fentanyl pills that the DEA chose not to seize. Overdose deaths are notoriously difficult to trace back to specific shipments. But for families in New Mexico and elsewhere who lost loved ones during the period these operations were active, the question is not academic.
When the agency tasked with stopping deadly drugs decides to let them keep moving, someone owes the public an answer for what went wrong and who paid the price.
